Dr Wolfgang Bäurle
GeneriNobel is a privately owned pharmaceutical company, based in Germany, which outlicenses generic drugs (Rx) and OTC developments for the European market.
Key therapeutic areas are cardiovascular diseases, central nervous system and metabolism. GeneriNobel has a focus on dossier development, registration and outlicensing of generic / OTC drugs and represents the marketing authorization / dossier portfolio of its partner, the turkish multinational pharmaceutical company Nobel Ilaç (own R&D and manufacturing of APIs and finished products).
We offer:
* Out-licensing of generic / OTC drugs (dossiers) at an advanced stage of regulatory approval procedure, e. g. Rosuvastatin.
* Out-licensing of generic / OTC drugs (marketing authorisations / dossiers) with granted marketing authorisations in Germany and which are available for further registration procedures in Europe, e. g. Solifenacin, Rasagiline, Duloxetine, Aripiprazole, Memantine, Irbesartan and Irbesartan-HCTZ, Sildenafil, Escitalopram, Pantoprazole and Omeprazole.
We are interested in:
Marketing and Sales companies who are interested to in-license products of our Portfolio.
We are NOT interested in:
* regulatory service providers, IP service providers, legal advisors, APIs.
GeneriNobel GmbH
Managing DirectorMr Juergen Beck
Boehringer Ingelheim Corporate Center GmbH
Head of Strategic Transactions & Alliance ManagementMs Mariana Brea-Krueger
IMI Consulting is Europe’s leading Management Consultancy and Advisory in Life Sciences having a track-record of over 27 years in servicing its clients. Because of IMI’s 150 Associate Partner network, it provides most forms of transaction and therapeutic expertise on a worldwide basis:
Strategy Development (market intelligence, development of new ways to compete, pipeline and segment analysis, Market Access and Pricing, Strategic Plans and Planning, etc.), Transaction Support (usually as implementation of the strategy, BD&L, Mergers & Acquisitions including spin-outs ) and Capital Raising.
IMI raises capital from seed to Round C, from VCs to private investors (HNW-angels).
Its 150 Associate Partner base allows specialization in most therapeutic sectors servicing Big & Specialty Pharma, Biotech, Diagnostic, MedTech, e-health and OTC/Nutritionals:
Addiction, Analgesics, Rheumatoid Arthritis, Cancer, Cardiovascular, CNS, Dermatology, Endocrinology, Gynecology, Urology, Gastrointestinal, Hematology, Life-Cycle Management, Metabolic, Molecular Diagnostics, Respiratory, Robotics, Genetic Editing, Nutritionals, OTCs, Transplantation, etc.
We cover all of Europe, USA and Asia.
Kathrin Casula
Helm AG is a Hamburg- based, privately owned company and represented by own subsidiaries in more
than 30 countries worldwide.
In cooperation with highly acclaimed international partners, Helm offers developments of generic
pharmaceuticals, IP researches, registrations of high quality e-CTD dossiers, launch and life cycle
management.
Our global presence and extensive variety of excellent service functions mean that Helm is your ideal
partner for all stages of the product life cycle from the initial idea generation through to the launch and
supply of the medicinal product.
We offer:
-High quality e-CTD dossiers per current EU-requirements and international registration strategies.
-Tailor made portfolio ideas.
- Excellent project management
- Collaborations for innovative technology platforms.
We are interested in:
- Identifying out-licensing and co-operation opportunities - especially for EU, Nordics, UK, LATAM, MENA
& CIS markets.
- Exploring product & brand acquisition opportunities in the targeted territories.
- Divestment of companies
We are NOT interested in:
- Regulatory Services
- CRO + CMO Services
Helm AG
Senior Licensing ManagerMs Ulrike Däxl
Specialized Pharma M&A Boutique operating since 1991 globally